Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

383Citations
Citations of this article
208Readers
Mendeley users who have this article in their library.

Abstract

Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post-liver transplantation recurrence represents a high unmet medical need with no approved therapies effective across all HCV genotypes. The open-label ALLY-1 study assessed the safety and efficacy of a 60-mg once-daily dosage of daclatasvir (pan-genotypic NS5A inhibitor) in combination with sofosbuvir at 400 mg once daily (NS5B inhibitor) and ribavirin at 600 mg/day for 12 weeks with a 24-week follow-up in two cohorts of patients with chronic HCV infection of any genotype and either compensated/decompensated cirrhosis or posttransplantation recurrence. Patients with on-treatment transplantation were eligible to receive 12 additional weeks of treatment immediately after transplantation. The primary efficacy measure was sustained virologic response at posttreatment week 12 (SVR12) in patients with a genotype 1 infection in each cohort. Sixty patients with advanced cirrhosis and 53 with posttransplantation recurrence were enrolled; HCV genotypes 1 (76%), 2, 3, 4, and 6 were represented. Child-Pugh classifications in the advanced cirrhosis cohort were 20% A, 53% B, and 27% C. In patients with cirrhosis, 82% (95% confidence interval [CI], 67.9%-92.0%) with genotype 1 infection achieved SVR12, whereas the corresponding rates in those with genotypes 2, 3, and 4 were 80%, 83%, and 100%, respectively; SVR12 rates were higher in patients with Child-Pugh class A or B, 93%, versus class C, 56%. In transplant recipients, SVR12 was achieved by 95% (95% CI, 83.5%-99.4%) and 91% of patients with genotype 1 and 3 infection, respectively. Three patients received peritransplantation treatment with minimal dose interruption and achieved SVR12. There were no treatment-related serious adverse events. Conclusion: The pan-genotypic combination of daclatasvir, sofosbuvir, and ribavirin was safe and well tolerated. High SVR rates across multiple HCV genotypes were achieved by patients with post-liver transplantation recurrence or advanced cirrhosis.

References Powered by Scopus

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

6263Citations
N/AReaders
Get full text

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1516Citations
N/AReaders
Get full text

The global burden of hepatitis C

1134Citations
N/AReaders
Get full text

Cited by Powered by Scopus

EASL Recommendations on Treatment of Hepatitis C 2018

1488Citations
N/AReaders
Get full text

EASL Recommendations on Treatment of Hepatitis C 2016

0
984Citations
N/AReaders
Get full text

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

842Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Poordad, F., Schiff, E. R., Vierling, J. M., Landis, C., Fontana, R. J., Yang, R., … Swenson, E. S. (2016). Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology, 63(5), 1493–1505. https://doi.org/10.1002/hep.28446

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 80

68%

Researcher 22

19%

Professor / Associate Prof. 13

11%

Lecturer / Post doc 3

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 101

74%

Biochemistry, Genetics and Molecular Bi... 16

12%

Pharmacology, Toxicology and Pharmaceut... 12

9%

Immunology and Microbiology 7

5%

Save time finding and organizing research with Mendeley

Sign up for free